Literature DB >> 17560655

Trends in candidemia and antifungal susceptibility in a university hospital in Northern Ireland 2001-2006.

L Metwally1, M J Walker, P V Coyle, R J Hay, S Hedderwick, B V McCloskey, H J O'Neill, C H Webb, R McMullan.   

Abstract

OBJECTIVES: To describe the species distribution and antifungal susceptibility trends for documented episodes of candidemia at the Royal Hospitals, Belfast, 2001-2006.
METHODS: Laboratory-based retrospective observational study of all episodes of candidemia.
RESULTS: There were 151 episodes of candidemia. The species recovered were: 96 C. albicans; 26 C. glabrata; 18 C. parapsilosis; five C. tropicalis; four C. guilliermondii; one C. famata and one C. dubliniensis. We separated the data into two periods 2001-2003 and 2004-2006; contrary to the findings of other investigators, there was a notable trends toward increasing frequency of C. albicans and decreasing frequency of non-albicans species over time. Although the proportion of C. albicans, C. parapsilosis and C. tropicalis isolates susceptible to fluconazole was unchanged over time, a trend of decreased susceptibility of C. glabrata to fluconazole was noted over the six-year period. Overall, 73% and 7.7% of C. glabrata isolates had susceptible-dose-dependent and resistant phenotypes, respectively. The percentage of C. glabrata isolates susceptible to fluconazole (MIC <8 microg/ml) decreased from 36% in 2001-2003 to 0% in 2004-2006. Flucytosine resistance was detected in only 4 (2.7%) isolates. None of the isolates had an amphotericin B MIC <1 microg/ml.
CONCLUSION: A shift towards increasing dominance of C. albicans contrasts both with reports from other countries and previous data from Northern Ireland. Upwards fluconazole MIC drift among C. glabrata has important implications for empirical therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560655     DOI: 10.1016/j.jinf.2007.04.003

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  4 in total

Review 1.  What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.

Authors:  Matteo Bassetti; Elda Righi; Philippe Montravers; Oliver A Cornely
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

2.  Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral candidiasis without culture evidence.

Authors:  Brenda A McManus; Eleanor McGovern; Gary P Moran; Claire M Healy; June Nunn; Pádraig Fleming; Colm Costigan; Derek J Sullivan; David C Coleman
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

3.  Candidemia due to Candida guilliermondii in an immuno-compromised infant: a case report and review of literature.

Authors:  Fatemeh Ahangarkani; Hamid Badali; Mohammad Sadegh Rezai; Tahereh Shokohi; Zahra Abtahian; Hassan Mahmoodi Nesheli; Hossein Karami; Emmanuel Roilides; Ahmad Tamaddoni
Journal:  Curr Med Mycol       Date:  2019-03

4.  Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen.

Authors:  Ziauddin Khan; Suhail Ahmad; Leena Joseph; Rachel Chandy
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.